STRS Ohio’s Neuropace NPCE Stock Holding History

STRS Ohio’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,600	Closed	-$38K	–	2293
2021 Q2	$38K	Buy	+1,600	New	+$37.1K	﹤0.01%	2138

Other funds holding NPCE

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

STRS Ohio's NPCE Position: Q3 2021 in Review

STRS Ohio sold out of Neuropace (NPCE) in Q3 2021, closing a stake of 1,600 shares — an estimated $38K sold.

STRS Ohio first reported a position in NPCE in Q2 2021 and held it in 1 quarter. The position peaked at $38K in Q2 2021. 39 funds tracked by Wall St. Rank hold NPCE as of Q3 2021.

STRS Ohio reported no remaining Neuropace position as of Q3 2021 after selling out during the quarter.
STRS Ohio sold 1,600 Neuropace shares in Q3 2021, an estimated $38K.
STRS Ohio first reported a position in Neuropace in Q2 2021 and held it in 1 quarter.
STRS Ohio's Neuropace position peaked at $38K in Q2 2021.
39 funds tracked by Wall St. Rank held Neuropace as of Q3 2021.

Based on STRS Ohio's 13F filing for Q3 2021, filed 22 Oct 2021.